CFRX
- ContraFect Corporation
()
Overview
Company Summary
ContraFect Corporation (CFRX) is a biotechnology company that focuses on the discovery and development of therapeutic products to combat serious and life-threatening infections. They specialize in the field of immunotherapy, utilizing the power of the human immune system to target and eliminate harmful pathogens.
The primary aim of ContraFect is to develop innovative treatments for antibiotic-resistant bacteria, which have become a major global health concern. They utilize a unique approach called lysin therapy, which involves the use of genetically modified naturally occurring human proteins, known as lysins, to selectively target and kill harmful bacteria.
CFRX is engaged in the development of multiple proprietary lysins targeting various bacterial infections, including Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, and Pseudomonas aeruginosa. These bacteria pose significant threats to patients in hospitals, as well as individuals with compromised immune systems.
To accelerate the development of their lysin therapies, ContraFect employs cutting-edge techniques such as protein engineering and molecular biology. They conduct extensive research, clinical trials, and collaborations with leading academic institutions and hospitals to validate the efficacy and safety of their products.
In addition to their lysin therapy pipeline, ContraFect also focuses on the development of monoclonal antibodies (mAbs). These antibodies are designed to neutralize and target specific bacteria, working alongside the immune system to eliminate infections.
In summary, ContraFect Corporation is a biotechnology company dedicated to developing innovative therapies to combat antibiotic-resistant bacterial infections. Through their focus on lysin therapy and monoclonal antibodies, they aim to save lives and improve patient outcomes in the face of a growing global health crisis.